Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 78Stomach Neoplasms 14Neoplasms 8Neoplasm Metastasis 8HER2-positive Breast Cancer 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Recurrence 2Ovarian Neoplasms 2Cardiotoxicity 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Meningeal Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

pembrolizumab 1cabozantinib 1apatinib 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Adenoid Cystic × Trastuzumab × Clear all
NCT03680560 2020-03-31

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Cogent Biosciences, Inc.

Phase 1 Terminated
6 enrolled
BreastGastrointestinal

Breast Neoplasms, Carcinoma, Adenoid Cystic, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡